Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2012
05/10/2012WO2012061602A1 Isoindolinone kinase inhibitors
05/10/2012WO2012061601A1 Treatment of pituitary corticotroph tumors using r-roscovitine
05/10/2012WO2012061597A1 Alpha-glucosidase binders and methods of their use
05/10/2012WO2012061576A1 Crystalline forms of ( s ) - 2 - amino - 3 - (4 - ( 2 - amino - 6 - ( (r) - 1 - (4 - ch loro-2- (3 -methyl- 1h- pyrazol- 1 -yl) phenyl) - 2, 2, 2 - trifluoroethoxy) pyrimidin- 4 - yl) phenyl) propanoic acid
05/10/2012WO2012061565A1 Solid forms of 3-(4-(aminomethyl)-1-(5-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate
05/10/2012WO2012061557A2 Chemical compounds
05/10/2012WO2012061552A1 Novel inhibitors of hepatitis c virus
05/10/2012WO2012061551A1 Administration of nedd8-activating enzyme inhibitor
05/10/2012WO2012061505A1 Methods and compositions for prevention and treatment of cardiac hypertrophy
05/10/2012WO2012061502A2 Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
05/10/2012WO2012061469A2 Crystalline forms of pralatrexate
05/10/2012WO2012061459A1 Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
05/10/2012WO2012061428A2 Nicotinamides as jak kinase modulators
05/10/2012WO2012061415A1 Oxypyrimidines as syk modulators
05/10/2012WO2012061413A2 Isoflavonoid compositions and methods for the treatment of cancer
05/10/2012WO2012061409A1 Isoflavonoid compounds and methods for the treatment of cancer
05/10/2012WO2012061402A2 System and method for delivery of dna-binding chemotherapy drugs using nanoparticles
05/10/2012WO2012061400A2 Method for reduction of free polysaccharide in polysaccharide-protein vaccines reactions using ion-exchange matrices
05/10/2012WO2012061395A2 Cytotoxic agents against cancer cells and uses thereof
05/10/2012WO2012061390A2 Therapeutic compositions and methods
05/10/2012WO2012061360A2 Pharmaceutical compositions
05/10/2012WO2012061342A2 Substituted benzo-imidazo-pyrido-diazepine compounds
05/10/2012WO2012061337A1 Fgfr2 modulators
05/10/2012WO2012061303A1 Heteroaryl compounds and uses thereof
05/10/2012WO2012061299A1 Heterocyclic compounds and uses thereof
05/10/2012WO2012061290A2 Pesticidal compositions and processes related thereto
05/10/2012WO2012061289A2 Methods for treatment of brain injury utilizing biologics
05/10/2012WO2012061288A1 Pesticidal compositions and processes related thereto
05/10/2012WO2012061260A1 Anti-staphylococcal celecoxib derivatives
05/10/2012WO2012061248A2 Novel specific hcv ns3 protease inhibitors
05/10/2012WO2012061190A1 Alkylsulfinyl-substituted thiazolide compounds
05/10/2012WO2012061169A1 Benzimidazole inhibitors of leukotriene production
05/10/2012WO2012061165A2 Methods and compositions for improving admet properties
05/10/2012WO2012061156A1 Cdk inhibitors
05/10/2012WO2012061094A1 Fatty amides and derivatives from natural oil metathesis
05/10/2012WO2012061086A2 Method of treating neuroendocrine tumors
05/10/2012WO2012061062A1 Use of teriflunomide for improving motor function
05/10/2012WO2012061061A1 Pharmaceutical formulations of a substituted diaminopurine
05/10/2012WO2012061060A1 Use of teriflunomide for treating brain atrophy
05/10/2012WO2012061057A1 Methods of treatment and/or prevention of scleroderma, uv injury or sunburn, formation of scars or keloids by using haloaryl substituted aminopurines
05/10/2012WO2012061019A2 Tricyclic mglur5 receptor modulators
05/10/2012WO2012061015A2 L-citrulline supplementation during arginine depletion therapy with arginase
05/10/2012WO2012061012A2 4-amino-2h-pyran-2-one analogs as anticancer agents
05/10/2012WO2012060860A1 Treatment of ocular and cerebral ischemia
05/10/2012WO2012060854A1 Purified crocetin compound and method for treating, inhibiting, and/or prophylaxis of cancer, such as pancreatic cancer
05/10/2012WO2012060845A1 Methods of preventing ischemic injury using peripheral nociceptive stimulation
05/10/2012WO2012060844A1 A2a antagonists as cognition and motor function enhancers
05/10/2012WO2012060820A1 Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
05/10/2012WO2012060793A2 Process for the preparation of cefdinir formulations
05/10/2012WO2012060792A1 Pharmaceutical compositions comprising minimum 6 % of disintegrants by weight
05/10/2012WO2012060791A2 Production method for pharmaceutical compositions comprising cefdinir
05/10/2012WO2012060790A2 Water dispersible cefpodoxime proxetil formulations
05/10/2012WO2012060789A2 Production method for cefdinir formulations
05/10/2012WO2012060788A1 Formulations of cephalosporins with controlled moisture content
05/10/2012WO2012060787A1 Oral dosage forms comprising cefdinir and carboxymethyl cellulose calcium
05/10/2012WO2012060786A2 Cefpodoxime proxetil formulations comprising viscosity agent
05/10/2012WO2012060785A1 Production method for tablets comprising cephalosporin
05/10/2012WO2012060783A1 THE USE OF β-D-GLUCAN TO REDUCE THE ADVERSE EFFECT OF THE IMMUNE RESPONSE DEPRESSION INDUCED BY EXCESSIVE PHYSICAL EXERCISE
05/10/2012WO2012060738A1 CLATHRATE COMPLEXES OF β-CYCLODEXTRIN WITH 1-{[6-BROMO-1-METHYL-5-METHOXY-2-PHENYLTHIOMETHYL-1-H-INDOLE-3-YL]CARBONYL}-4-BENZYLPIPERAZINE HAVING ANTIVIRAL ACTIVITY, THE PRODUCTION AND USE THEREOF
05/10/2012WO2012060719A1 A combination composition
05/10/2012WO2012060718A1 Preventing or treating metabolic syndrome by administering a trans fatty acid, or a salt, ester or precursor thereof, or sialic acid in free or bound form
05/10/2012WO2012060594A2 Anti-inflammatory composition containing a thiourea compound and a pharmaceutically acceptable salt thereof as an active ingredient
05/10/2012WO2012060590A2 Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate
05/10/2012WO2012060482A1 Cdk-inhibiting pyrrolopyrimidinone carboxamide derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient for preventing or treating liver cell cancer
05/10/2012WO2012060448A1 Combined pharmaceutical composition as antifungal agent
05/10/2012WO2012060431A1 Patch
05/10/2012WO2012060397A1 Preventive or therapeutic agent for pain associated with herpes zoster in acute phase
05/10/2012WO2012060396A1 Trans-2-decenoic acid derivative and medicament containing same
05/10/2012WO2012060388A1 Organic amine salt of aminobenzoic acid derivative, and method for producing same
05/10/2012WO2012060387A1 Novel dihydroxybenzene derivatives and antiprotozoal agent comprising same as active ingredient
05/10/2012WO2012060376A1 Felbinac-containing external patch
05/10/2012WO2012060308A1 Medicine for preventing and treating renal dysfunction
05/10/2012WO2012060109A1 Method of examining polycystic kidney disease and method of screening for therapeutic agent of the disease
05/10/2012WO2012059942A2 Dynamic balancing of autonomic nervous system through vitamin mk-7
05/10/2012WO2012059941A1 Process for preparation of sunitinib malate and salts thereof
05/10/2012WO2012059937A1 Modifies release pharmaceutical compositons for nsaids
05/10/2012WO2012059935A1 Process for preparing bendamus tine hydrochloride monohydrate
05/10/2012WO2012059932A1 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
05/10/2012WO2012059920A1 Ladostigil dosage regime
05/10/2012WO2012059884A1 Novel self-assembling polyphenol-quinonoid polymer derivatives and uses thereof
05/10/2012WO2012059869A1 Gpr17-modulating compounds, diagnostic and therapeutic uses thereof
05/10/2012WO2012059823A1 Process for the preparation of phosphoric acid mono- (l-{4- [(s) -5- (acetylaminomethyl) - 2 - oxo - oxazolidin- 3 - yl] - 2, 6 - difluorophenyl} - 4 -methoxymethylpiperidin- 4 - yl) ester
05/10/2012WO2012059818A1 Methods of treatment using lipid compounds
05/10/2012WO2012059815A1 Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms
05/10/2012WO2012059776A1 Indole derivatives
05/10/2012WO2012059725A1 Peg or peg block copolymers for treating colorectal cancer
05/10/2012WO2012059724A1 Formulations comprising polyethylene glycol
05/10/2012WO2012059685A1 Method for decontaminating starch hydrolysates for the preparation of glucose polymers for peritoneal dialysis
05/10/2012WO2012059598A2 Methods of treating rheumatoid arthritis using il-17 antagonists
05/10/2012WO2012059594A1 Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
05/10/2012WO2012059572A1 COMBINATION OF ATOMIC QUANTUM CLUSTERS (AQCs) AND ANTINEOPLASIC DRUGS, AND ITS USE IN THE PREVENTION AND/OR TREATMENT OF CELL PROLIFERATIVE DISORDERS
05/10/2012WO2012059571A1 USE OF ATOMIC QUANTUM CLUSTERS (AQCs) IN THE PREVENTION OF AUTOIMMUNE DISEASES
05/10/2012WO2012059570A1 USE OF ATOMIC QUANTUM CLUSTERS (AQCs) IN THE PREVENTION OF VIRAL INFECTIONS
05/10/2012WO2012059568A1 Novel water-soluble indolobenzazepine molecules demonstrating antimitotic, antivascular, and antitumor activities in vivo
05/10/2012WO2012059549A1 Substituted 6-fluoro-1h-pyrazolo[4,3-b]pyridines and use thereof
05/10/2012WO2012059548A1 Benzyl-substituted carbamates and use thereof
05/10/2012WO2012059541A1 Novel treatment of multiple sclerosis (ms)
05/10/2012WO2012059526A1 Treatment of mastocytosis with masitinib
05/10/2012WO2012059515A1 Kit for the localized activation of high concentrations of a drug and the procedure thereof
05/10/2012WO2012059507A1 Pyrrolidine derivatives used as cathepsin inhibitors
1 ... 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 ... 7860